PDB33 The Associated Costs of Treating Type 2 Diabetes Patients to a Clinically Relevant Composite Endpoint With Liraglutide Versus Exenatide
Jun 1, 2012, 00:00
10.1016/j.jval.2012.03.954
https://www.valueinhealthjournal.com/article/S1098-3015(12)01019-4/fulltext
Title :
PDB33 The Associated Costs of Treating Type 2 Diabetes Patients to a Clinically Relevant Composite Endpoint With Liraglutide Versus Exenatide
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)01019-4&doi=10.1016/j.jval.2012.03.954
First page :
A176
Section Title :
Diabetes/Endocrine Disorders
Open access? :
No
Section Order :
448